Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

sales@dingminpharma.com

86-311-67591193

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
HomeProductsOthersNintedanib ethanesulfonate salt 656247-18-6

Nintedanib ethanesulfonate salt 656247-18-6

  • $50
    ≥1
    Gram
Payment Type:
L/C,T/T,D/A,Paypal
Incoterm:
FOB,CIF
Min. Order:
1 Gram
Transportation:
Ocean,Air,Express
Port:
shanghai,hangzhou
Share:
  • Product Description
Overview
Product Attributes

Model No.656247-18-6

BrandDM

Supply Ability & Additional Information

Packagingas per request

Productivity100kgs/month

TransportationOcean,Air,Express

Place of OriginHebei,China

Supply Ability100kgs/month

CertificateISO9001

Portshanghai,hangzhou

Payment TypeL/C,T/T,D/A,Paypal

IncotermFOB,CIF

Packaging & Delivery
Selling Units:
Gram
Package Type:
as per request
Picture Example:

Product name
CAS NO.
656247-18-6
Appearance
white powder
Category
Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.
Standard
purity:>99%
Shelf life
2 years
Nintedanib Introduction

Nintedanib is the first FDA-approved drug for the management of idiopathic pulmonary fibrosis (IPF), a rare but often fatal lung disease. Nintedanib is believed to exert its mechanism of action by inhibiting multiple receptor tyrosine kinases, including those that have been implicated in the pathogenesis of IPF (i.e., fibroblast growth factor receptor, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor). Nintedanib also inhibits nonreceptor tyrosine kinases, although the contribution of this inhibition in the efficacy of the drug is unknown.

Function

Nintedanib BIBF (1120) is a kind of indole moiety ketone derivative oral activity of triple kinase inhibitor, on the vascular endothelial growth factor receptor (VEGFR1/2/3), fibroblast growth factor receptor (FGFR1/2/3) and platelet-derived growth factor receptor (PDGFR alpha/beta) has inhibitory effect, in the Moore (IC50, 20-100 nmol/L) of scope by blocking these receptor mediated signal pathway, with effective anti-angiogenesis activity . Nintedanib (BIBF 1120) can be used in clinical studies in the treatment of idiopathic pulmonary fibrosis because these receptors may be involved in the pathogenesis of pulmonary fibrinolysis [3,4]. As a novel angiogenic inhibitor, Nintedanib has also been widely evaluated in various cancer models, and it exerts significant anti-tumor activity by inhibiting tumor angiogenesis

COA
Item
Specification
Results
Appearance
White Powder
White Powder
Assay
99.0%--101.0%(Anhydrous substance)
99.98%
Purity
≥99.0%
99.89%
Water
≤1.0%
0.1%
Sulphated ash
≤0.5%
0.045%
Related substances
Unspecified impurities for each impurity
Complies
Heavy Metals
≤10ppm
<10ppm
Loss On Drying
≤2.0%
0.19%

Product Categories : Others

Email to this supplier
  • *Subject:
  • *To:
    Ms. Lily
  • *Email:
  • *Message:
    Your message must be between 20-8000 characters
HomeProductsOthersNintedanib ethanesulfonate salt 656247-18-6
Send Inquiry
*
*

Related Products List

Home

Product

Phone

About Us

Inquiry

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Send